The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.
 
Makoto Ueno
Honoraria - Abbott Japan; AstraZeneca Japan; Boston Scientific; Kyowa Hakko Kirin; Lilly; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca Japan; Baxalta; Daiichi Sankyo; Eisai; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Zeria Pharmaceutical
 
Shinichi Ohkawa
Honoraria - Lilly; Otsuka; Sandoz; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst)
 
Noritoshi Kobayashi
No Relationships to Disclose
 
Kazuya Sugimori
No Relationships to Disclose
 
Yoshiaki Kawaguchi
No Relationships to Disclose
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Novartis
 
Masataka Taguri
No Relationships to Disclose
 
Takeharu Yamanaka
No Relationships to Disclose
 
Tetsuya Mine
No Relationships to Disclose